Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 576 - 600 of 14525 in total

Sinapultide

Sinapultide (also known as KL4 peptide) is a synthetic protein used to mimic human lung surfactant protein B. This protein has a weight of 2469.40. Sinapultide is a 21-residue peptide made up of lysine (K) and leucine (L) residues with the sequence KLLLLKLLLLKLLLLKLLLLK (KL4), in aqueous dispersion with the phospholipids...
Approved
Matched Description: … Surfactant replacement therapy has been commonly used to prevent and treat RDS in these newborns and ... [L2502] Sinapultide is a 21-residue peptide made up of lysine (K) and leucine (L) residues with the ... [L2505] Respiratory distress syndrome (RDS) is a major cause of mortality and morbidity in preterm …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Sulfamethizole

A sulfathiazole antibacterial agent.
Approved
Investigational
Vet approved
Matched Categories: … Blood and Blood Forming Organs ... Sulfonamides and trimethoprim ... Genito Urinary System and Sex Hormones ... Blood Substitutes and Perfusion Solutions ... Gynecological Antiinfectives and Antiseptics …

Insulin glargine

Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … and proteolysis. ... tissues such as the liver, fat cells, and skeletal muscle. ... addition of two arginines to the C-terminus (positions B31 and 32) of the B-chain. …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... insulin glargine and lixisenatide ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Buserelin

Buserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR). It is used in prostate cancer treatment.
Approved
Investigational
Matched Categories: … Hormones and Related Agents ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Cyclothiazide

As a diuretic, cyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like cyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter....
Approved
Matched Description: … corticosteroid and estrogen therapy. ... tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and ... indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and …
Matched Categories: … cyclothiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Fludeoxyglucose (18F)

Fludeoxyglucose F 18 Injection is a positron emitting radiopharmaceutical containing no-carrier added radioactive 2-deoxy-2-[18F]fluoro-D-g1ucose, which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET). It is administered by intravenous injection.
Approved
Investigational
Matched Categories: … Indicators and Reagents …

Lactulose

Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929 , investigations regarding its possible use as a laxative for...
Approved
Matched Description: … possible use as a laxative for the treatment of chronic constipation did not occur until the 1960s and ... [L6202] Nevertheless, although lactulose received formal FDA approval in 1977 and has since become ... List of Essential Medicines as one of the most effective and safe medicines employed in a health system …
Matched Categories: … Alimentary Tract and Metabolism …

Aurothioglucose

Aurothioglucose, also known as gold thioglucose, was formerly used to treat rheumatoid arthritis. Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and to slow disease progression in patients with rheumatoid arthritis . The use of gold compounds has decreased since the 1980s...
Approved
Withdrawn
Matched Description: … use of gold compounds has decreased since the 1980s owing to numerous side effects, limited efficacy, and ... Contemporary research on the effect of gold salts treatment began in 1935, primarily to reduce inflammation and ... replaced with the use of various current disease modifying anti-rheumatic drugs (DMARDs) like methotrexate and …
Matched Categories: … Antiinflammatory and Antirheumatic Products …

Toripalimab

The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance. One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1) - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the...
Approved
Investigational
Matched Description: … production, and thus its overexpression can inhibit T-cell-mediated immune surveillance of tumors. ... through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and ... PD-L2) to its target receptor (PD-1) results in the inhibition of T-cell proliferation and cytokine …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Naxitamab

Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within...
Approved
Matched Description: … [L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and ... within neuroblastomas (and other neuroectodermal tumors),[A224609] and is rarely subject to antigen ... constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Pitavastatin

Pitavastatin, also known as the brand name product Livalo, is a lipid-lowering drug belonging to the statin class of medications. By inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and lipid levels and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively...
Approved
Matched Description: … lipid levels and ultimately reduce the risk of cardiovascular disease. ... studies to significantly reduce the risk of development of CVD and all-cause mortality. ... inhibiting the endogenous production of cholesterol within the liver, statins lower abnormal cholesterol and …

Artemotil

Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting blood schizonticide specifically indicated for the treatment of chloroquine-resistant Plasmodium falciparum malaria and cerebral malaria cases.
Approved
Matched Description: … Artemotil, also known as β-arteether, is a semi-synthetic derivative of artemisinin and a fast acting ... schizonticide specifically indicated for the treatment of chloroquine-resistant _Plasmodium falciparum_ malaria and …
Matched Categories: … Artemisinin and derivatives ... Antiparasitic Products, Insecticides and Repellents …

Tebentafusp

Tebentafusp is a gp100 peptide-HLA-directed CD3 T cell engager. It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism of action. ImmTACs bind to target cancer cells that express a specific antigen of...
Approved
Investigational
Matched Description: … [L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T ... ImmTACs bind to target cancer cells that express a specific antigen of interest and recruit cytotoxic ... being the first and only therapy for the treatment of unresectable or metastatic uveal melanoma to be …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Mebrofenin

Approved
Experimental
Matched Categories: … Amino Acids, Peptides, and Proteins …

Donislecel

Donislecel is the first allogeneic pancreatic islet cellular from deceased donor pancreatic cells used for the treatment of adult type 1 diabetes with unsuccessful control of glycated hemoglobin, despite intensive diabetes management and treatments.[L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and other...
Approved
Matched Description: … 1 diabetes with unsuccessful control of glycated hemoglobin, despite intensive diabetes management and ... other pancreatic hormones from infused allogeneic islet cells to mimic endogenous glucose control and ... L47166,L47196] The primary mechanism of action of donislecel is attributed to the secretion of insulin and …
Matched Categories: … Cellular and Gene Therapy …

Empagliflozin

Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor...
Approved
Matched Description: … led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014 ... the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart ... [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and empagliflozin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin …

Onasemnogene abeparvovec

Onasemnogene abeparvovec is an adeno-associated virus vector-based gene therapy that has been approved by the FDA in May 2019 for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene. SMA is...
Approved
Matched Description: … to debilitating and often fatal muscle weakness. ... for the treatment of infant patients (less than 2 years of age) with spinal muscular atrophy (SMA) and ... complete paralysis of the limbs and permanent dependence on ventilators, has not been evaluated. …
Matched Categories: … Cellular and Gene Therapy ... Amino Acids, Peptides, and Proteins …

Dihydrostreptomycin

Dihydrostreptomycin is an aminoglycoside antibiotic. In humans, the use of dihydrostreptomycin has been associated with ototoxicity. The FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.
Approved
Investigational
Vet approved
Withdrawn

Ofatumumab

Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is...
Approved
Matched Description: … In February 2020, FDA and EMA approved Supplemental Biologics License Application (sBLA) and Marketing ... [A6921] Ofatumumab is available for intravenous administration and is marketed as Arzerra. ... IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Eflapegrastim

Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia (ANC < 500 cells/mm3), is a potential side effect of myelosuppressive chemotherapy in which the patient develops an infection during a period of significant neutropenia. It typically develops during the first cycle of chemotherapy...
Approved
Investigational
Matched Description: … risk of morbidity and mortality. ... Febrile neutropenia (FN), defined as the co-occurrence of fever (temperature > 38 ◦C) and severe neutropenia ... [A252320] It typically develops during the first cycle of chemotherapy and is associated with an increased …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …

Alteplase

Alteplase is a recombinant tissue plasminogen activator (rt-PA) used as a thrombolytic agent. It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. In the absence of fibrin, the alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and fibrin.[A252330,L43125] Alteplase...
Approved
Investigational
Matched Description: … alteplase-mediated conversion of plasminogen is limited, thanks to the high affinity between alteplase and ... thrombolytic agents derived from tissue plasminogen activator, such as [desmoteplase], [tenecteplase] and ... alteplase to manage AMI has decreased thanks to the availability of safer treatments such as angioplasty and …
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …

Dexketoprofen

Dexketoprofen is a non-steroidal anti-inflammatory drug. It is available in the various countries in Europe, Asia and Latin America. It has analgesic, antipyretic and anti-inflammatory properties .
Approved
Investigational
Matched Description: … It has analgesic, antipyretic and anti-inflammatory properties [L1298]. ... It is available in the various countries in Europe, Asia and Latin America. …
Matched Categories: … Ketoprofen and isomer ... tramadol and dexketoprofen ... Antiinflammatory and Antirheumatic Products ... Topical Products for Joint and Muscular Pain ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Palifermin

Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004.
Approved
Matched Description: … It is 140 residues long, and is produced using E. coli. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Intercellular Signaling Peptides and Proteins …

Almasilate

Almasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by binding hydrogen ions within the polymer. However its therapeutic efficacy is not comparable to other approved antacids, as it is no more...
Approved
Experimental
Matched Description: … Almasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. ... It is a crystalline polyhydrate of aluminium/magnesium silicate and mediates its buffering activity by ... efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and …
Matched Categories: … Alimentary Tract and Metabolism ... Aluminum and magnesium containing antacids …

Lormetazepam

Lormatazepam is an orally available benzodiazepine used in the UK for the treatment of short-term insomnia . It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations.
Approved
Matched Description: … It is marketed by Auden Mckenzie (Pharma Division) in 0.5 and 1 mg tablet formulations. …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepines and benzodiazepine derivatives …
Displaying drugs 576 - 600 of 14525 in total